- Mechanism
- Ghrelin receptor (GHSR-1a) agonist
- Typical research dose
- 100-200 mcg/injection (research)
- Route
- Subcutaneous
- Half-life
- ~55 minutes
- Legal status
- Research Only
Overview
Hexarelin is a highly potent, synthetic growth hormone-releasing peptide (GHRP) that functions as a ghrelin receptor agonist to stimulate the secretion of endogenous growth hormone. This hexapeptide induces a robust release of growth hormone without significantly elevating cortisol or prolactin levels. Researchers are actively investigating the Hexarelin peptide for its profound cardioprotective properties, potential to mitigate ischemic injuries, and ability to modulate cellular apoptosis. Understanding Hexarelin benefits is crucial for advancing therapeutic strategies targeting cardiovascular disease, metabolic disorders, and tissue regeneration.
Potential Benefits
- Cardiovascular Protection: Research indicates that Hexarelin exerts direct cardioprotective effects, mitigating angiotensin II-induced cardiac hypertrophy and improving heart function Agbo E et al., 2019.
- Atherosclerosis Reduction: The peptide attenuates atherosclerosis by inhibiting macrophage uptake of oxidized LDL through the LOX-1-NF-κB signaling pathway Cheng XL et al., 2019.
- Neuroprotection: Hexarelin modulates MAPK and PI3K/Akt pathways to protect neuronal cells from oxidative stress and apoptotic toxicity Meanti R et al., 2021.
- Acute Kidney Injury Mitigation: Studies demonstrate that Hexarelin alleviates apoptosis in ischemic acute kidney injury by regulating the MDM2/p53 pathway Guan C et al., 2023.
- Lung Inflammation Reduction: In models of acute lung injury, the peptide successfully modulates lung mechanics, reduces inflammation, and prevents fibrotic tissue remodeling Zambelli V et al., 2021.
- Aortic Aneurysm Prevention: Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting smooth muscle cell phenotype switching and inflammasome activation Jiang B et al., 2022.
Where to Buy Hexarelin
Pinnacle Peptide Labs
View →Research compound. Hexarelin is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Mild injection site reactions including erythema or pruritus
- Transient increases in hunger or appetite
- Temporary lethargy or fatigue post-administration
- Mild water retention or peripheral edema
- Slight, transient elevations in cortisol or prolactin
Rare or serious side effects:
- Desensitization of pituitary growth hormone receptors with chronic use
- Insulin resistance or altered glucose metabolism
- Significant joint pain or nerve compression
- Exacerbation of pre-existing proliferative conditions
Hexarelin is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Growth hormone secretagogue receptor activation is the primary mechanism by which the Hexarelin peptide exerts its systemic effects. By binding to the ghrelin receptor (GHSR-1a) in the pituitary gland and hypothalamus, it triggers a G-protein coupled signaling cascade that leads to a massive, dose-dependent release of endogenous growth hormone. Unlike exogenous growth hormone administration, this pathway preserves the body's natural pulsatile rhythm and feedback loops, minimizing the suppression of natural hormone production Sigalos JT et al., 2018.
Targeted cellular pathway modulation explains the extensive cardioprotective and anti-apoptotic Hexarelin benefits observed in peripheral tissues. The peptide actively binds to CD36 receptors on cardiac cells and macrophages, inhibiting the LOX-1-NF-κB signaling pathway to reduce inflammation and atherosclerosis Cheng XL et al., 2019. Furthermore, it regulates autophagy and inhibits apoptosis in ischemic environments by modulating the MDM2/p53 and PI3K/Akt pathways, offering profound protection to the heart, kidneys, and nervous system Guan C et al., 2023.
Origin & History
Synthetic peptide development in the late 20th century led to the discovery of Hexarelin as researchers sought more stable and potent alternatives to natural growth hormone-releasing hormone (GHRH). Derived from the GHRP-6 molecular structure, Hexarelin was engineered by substituting specific amino acids to enhance its binding affinity to the ghrelin receptor and increase its resistance to enzymatic degradation. This structural optimization resulted in one of the most potent growth hormone secretagogues available, sparking extensive clinical interest in its application for age-related growth hormone decline and cardiovascular diseases Mao Y et al., 2014.
Current regulatory status designates the Hexarelin peptide strictly as a research-use-only compound. While it has undergone various phases of clinical investigation for conditions like congestive heart failure and growth hormone deficiency, it has not received approval from the FDA or EMA for human medical use. Ongoing research continues to explore its therapeutic viability, particularly regarding its unique ability to mitigate diabetes-associated heart diseases and prevent abdominal aortic aneurysm formation Mosa RM et al., 2015.